Jump to content

Pyrovalerone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Sandstein (talk | contribs) at 09:01, 14 July 2018 (Removing link(s): Wikipedia:Articles for deletion/Discontinuation closed as delete (XFDcloser)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pyrovalerone
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
Identifiers
  • (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.230.426 Edit this at Wikidata
Chemical and physical data
FormulaC16H23NO
Molar mass245.36 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C(C(CCC)N1CCCC1)C2=CC=C(C)C=C2
  • InChI=1S/C16H23NO/c1-3-6-15(17-11-4-5-12-17)16(18)14-9-7-13(2)8-10-14/h7-10,15H,3-6,11-12H2,1-2H3 checkY
  • Key:SWUVZKWCOBGPTH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pyrovalerone (Centroton, 4-Methyl-β-keto-prolintane, Thymergix, O-2371)[1] is a psychoactive drug with stimulant effects via acting as a norepinephrine-dopamine reuptake inhibitor (NDRI), and is used for the clinical treatment of chronic fatigue or lethargy[2] and as an anorectic or appetite suppressant for weight loss purposes. It was developed in the late 1960s and has since been used in France and several other European countries, and although pyrovalerone is still occasionally prescribed, it is used infrequently due to problems with abuse and dependence.[3] It is closely related on a structural level to a number of other stimulants, such as MDPV and prolintane (Promotil, Katovit).

Side effects of pyrovalerone include anorexia or loss of appetite, anxiety, fragmented sleep or insomnia, and trembling, shaking, or muscle tremors. Withdrawal following abuse upon discontinuation often results in depression.

The R-enantiomer of pyrovalerone is devoid of activity.[4]

See also

References

  1. ^ US Patent 3314970
  2. ^ Gardos, G.; Cole, J. O. (1971). "Evaluation of pyrovalerone in chronically fatigued volunteers". Current Therapeutic Research, Clinical and Experimental. 13 (10): 631–635. PMID 4402508.
  3. ^ Deniker, P.; Lôo, H.; Cuche, H.; Roux, J. M. (1975). "Abuse of pyrovalerone by drug addicts". Annales médico-psychologiques. 2 (4): 745–748. PMID 9895.
  4. ^ Meltzer, P. C.; Butler, D.; Deschamps, J. R.; Madras, B. K. (2006). "1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors". Journal of Medicinal Chemistry. 49 (4): 1420–1432. doi:10.1021/jm050797a. PMC 2602954. PMID 16480278.